Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.4.022

Roles of heterogenous hepatic macrophages in the progression of liver diseases  

Lee, Kyeong-Jin (Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University)
Kim, Mi-Yeon (Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University)
Han, Yong-Hyun (Laboratory of Pathology and Physiology, College of Pharmacy, Kangwon National University)
Publication Information
BMB Reports / v.55, no.4, 2022 , pp. 166-174 More about this Journal
Abstract
Hepatic macrophages are key immune cells associated with the broad ranges of liver diseases including steatosis, inflammation and fibrosis. Hepatic macrophages interact with other immune cells and orchestrate hepatic immune circumstances. Recently, the heterogenous populations of hepatic macrophages have been discovered termed residential Kupffer cells and monocyte-derived macrophages, and identified their distinct population dynamics during the progression of various liver diseases. Liver injury lead to Kupffer cells activation with induction of inflammatory cytokines and chemokines, which triggers recruitment of inflammatory monocyte-derived macrophages. To understand liver pathology, the functions of different subtypes of liver macrophages should be regarded with different perspectives. In this review, we summarize recent advances in the roles of hepatic macrophages under liver damages and suggest hepatic macrophages as promising therapeutic targets for treating liver diseases.
Keywords
Inflammation; Kupffer cells; Macrophage; Monocytes; NAFLD;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Koyama Y and Brenner DA (2017) Liver inflammation and fibrosis. J Clin Invest 127, 55-64   DOI
2 Lopez BG, Tsai MS, Baratta JL et al (2011) Characterization of Kupffer cells in livers of developing mice. Comp Hepatol 10, 2   DOI
3 Kupffer C (1876) Ueber Sternzellen der Leber. Archiv fur mikroskopische Anatomie 12, 353-358   DOI
4 van Furth R, Cohn ZA, Hirsch JG et al (1972) The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ 46, 845-852
5 Hoeffel G, Chen J, Lavin Y et al (2015) C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 42, 665-678   DOI
6 Gomez Perdiguero E, Klapproth K, Schulz C et al (2015) Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547-551   DOI
7 Bertrand JY, Jalil A, Klaine M et al (2005) Three pathways to mature macrophages in the early mouse yolk sac. Blood 106, 3004-3011   DOI
8 Heymann F and Tacke F (2016) Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13, 88-110   DOI
9 Fogg DK, Sibon C, Miled C et al (2006) A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311, 83-87   DOI
10 Seidman JS, Troutman TD, Sakai M et al (2020) Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity 52, 1057-1074.e7   DOI
11 Daemen S, Gainullina A, Kalugotla G et al (2021) Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep 34, 108626   DOI
12 Chakarov S, Lim HY, Tan L et al (2019) Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science 363, eaau0964   DOI
13 Chen G, Ning B and Shi T (2019) Single-cell RNA-Seq technologies and related computational data analysis. Front Genet 10, 317   DOI
14 van der Heide D, Weiskirchen R and Bansal R (2019) Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front Immunol 10, 2852   DOI
15 Friedman SL, Ratziu V, Harrison SA et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67, 1754-1767   DOI
16 Dapito DH, Mencin A, Gwak GY et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504-516   DOI
17 Carpino G, Del Ben M, Pastori D et al (2020) Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology 72, 470-485   DOI
18 Loomba R, Lawitz E, Mantry PS et al (2018) The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67, 549- 559   DOI
19 Han YH, Shin KO, Kim JY et al (2019) A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J Clin Invest 129, 1684-1698   DOI
20 Helmy KY, Katschke KJ Jr, Gorgani NN et al (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927   DOI
21 Miura K, Yang L, van Rooijen N et al (2012) Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 302, G1310-G1321   DOI
22 Guillot A and Tacke F (2019) Liver macrophages: old dogmas and new insights. Hepatol Commun 3, 730-743   DOI
23 Jiang Y, Tang Y, Hoover C et al (2021) Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice. Cell Death Differ 28, 3009-3021   DOI
24 Perez-Martinez L, Perez-Matute P, Aguilera-Lizarraga J et al (2014) Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 69, 1903-1910   DOI
25 Nascimento M, Huang SC, Smith A et al (2014) Ly6Chi monocyte recruitment is responsible for Th2 associated host-protective macrophage accumulation in liver inflammation due to schistosomiasis. PLoS Pathog 10, e1004282   DOI
26 Chalasani N, Abdelmalek MF, Garcia-Tsao G et al (2020) Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158, 1334-1345.e5   DOI
27 Chen Y and Tian Z (2021) Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer. Cell Mol Immunol 18, 57-72   DOI
28 Scott CL, Zheng F, De Baetselier P et al (2016) Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun 7, 10321   DOI
29 Soehnlein O and Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10, 427-439   DOI
30 Tacke F (2017) Targeting hepatic macrophages to treat liver diseases. J Hepatol 66, 1300-1312   DOI
31 Zigmond E, Samia-Grinberg S, Pasmanik-Chor M et al (2014) Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury. J Immunol 193, 344-353   DOI
32 Krenkel O and Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17, 306-321   DOI
33 Heymann F, Peusquens J, Ludwig-Portugall I et al (2015) Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62, 279-291   DOI
34 Zeng Z, Surewaard BG, Wong CH et al (2016) CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne Gram-positive bacteria. Cell Host Microbe 20, 99-106   DOI
35 Zheng M and Tian Z (2019) Liver-mediated adaptive immune tolerance. Front Immunol 10, 2525   DOI
36 Baeck C, Wehr A, Karlmark KR et al (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426   DOI
37 Varol C, Landsman L, Fogg DK et al (2007) Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med 204, 171-180   DOI
38 Henderson NC, Mackinnon AC, Farnworth SL et al (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103, 5060-5065   DOI
39 Harrison SA, Wong VW, Okanoue T et al (2020) Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 73, 26-39   DOI
40 Han YH, Kim HJ, Na H et al (2017) RORα induces KLF4-mediated M2 polarization in the liver macrophages that protect against nonalcoholic steatohepatitis. Cell Rep 20, 124-135   DOI
41 Iacobini C, Menini S, Ricci C et al (2011) Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 54, 975-983   DOI
42 Mridha AR, Wree A, Robertson AAB et al (2017) NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 66, 1037-1046   DOI
43 Ramachandran P, Pellicoro A, Vernon MA et al (2012) Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 109, 3186-3195
44 Xiong X, Kuang H, Ansari S et al (2019) Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell 75, 644-660.e5   DOI
45 Sutti S, Bruzzi S, Heymann F et al (2019) CX3CR1 mediates the development of monocyte-derived dendritic cells during hepatic inflammation. Cells 8, 1099   DOI
46 Wen Y, Lambrecht J, Ju C et al (2021) Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 18, 45-56   DOI
47 Franchi L, Eigenbrod T, Munoz-Planillo R et al (2009) The inflammasome: a caspase-1-activation platform that reguates immune responses and disease pathogenesis. Nat Immunol 10, 241-247   DOI
48 Zhang C, Feng J, Du J et al (2018) Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity. Cell Mol Immunol 15, 973-982   DOI
49 Guo Q, Furuta K, Lucien F et al (2019) Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol 71, 1193-1205   DOI
50 Cai J, Zhang XJ and Li H (2019) The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology 70, 1026-1037   DOI
51 Sanyal A, Boyer T, Terrault N et al (2017) Zakim and Boyer's hepatology: a textbook of liver disease. Philadelphia, PA: Elsevier
52 Mass E, Ballesteros I, Farlik M et al (2016) Specification of tissue-resident macrophages during organogenesis. Science 353, aaf4238   DOI
53 Browicz (1899) Ueber intravasculare Zellen in den Blutcapillaren der Leberacini. Archiv fur mikroskopische Anatomie 55, 420-426   DOI
54 David BA, Rezende RM, Antunes MM et al (2016) Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice. Gastroenterology 151, 1176-1191   DOI
55 Ritz T, Krenkel O and Tacke F (2018) Dynamic plasticity of macrophage functions in diseased liver. Cell Immunol 330, 175-182   DOI
56 Melgar-Lesmes P and Edelman ER (2015) Monocyte-endothelial cell interactions in the regulation of vascular sprouting and liver regeneration in mouse. J Hepatol 63, 917-925   DOI
57 Yona S, Kim KW, Wolf Y et al (2013) Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91   DOI
58 Mass E (2018) Delineating the origins, developmental programs and homeostatic functions of tissue-resident macrophages. Int Immunol 30, 493-501   DOI
59 Beattie L, Sawtell A, Mann J et al (2016) Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. J Hepatol 65, 758-768   DOI
60 Strnad P, Tacke F, Koch A et al (2017) Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol 14, 55-66   DOI
61 Jenne CN and Kubes P (2013) Immune surveillance by the liver. Nat Immunol 14, 996-1006   DOI
62 Lefere S, Puengel T, Hundertmark J et al (2020) Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol 73, 757-770   DOI
63 Mossanen JC, Krenkel O, Ergen C et al (2016) Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology 64, 1667-1682   DOI
64 Seki E, De Minicis S, Osterreicher CH et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13, 1324-1332   DOI
65 Tacke F and Zimmermann HW (2014) Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60, 1090-1096   DOI
66 Stutchfield BM, Antoine DJ, Mackinnon AC et al (2015) CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology 149, 1896-1909.e1814   DOI
67 Kruger AJ, Fuchs BC, Masia R et al (2018) Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun 2, 529-545   DOI
68 Ratziu V, Sanyal A, Harrison SA et al (2020) Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology 72, 892-905   DOI
69 Anstee QM, Neuschwander-Tetri BA, Wong VW et al (2020) Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials 89, 105922   DOI
70 Karlmark KR, Weiskirchen R, Zimmermann HW et al (2009) Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50, 261-274   DOI
71 Auffray C, Fogg D, Garfa M et al (2007) Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317, 666-670   DOI
72 Serbina NV and Pamer EG (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7, 311-317   DOI
73 Grunhut J, Wang W, Aykut B et al (2018) Macrophages in nonalcoholic steatohepatitis: friend or foe? Eur Med J Hepatol 6, 100-109
74 Bonnardel J, T'Jonck W, Gaublomme D et al (2019) Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche. Immunity 51, 638-654.e639   DOI
75 Sakai M, Troutman TD, Seidman JS et al (2019) Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity. Immunity 51, 655-670.e658   DOI
76 Braga TT, Agudelo JS and Camara NO (2015) Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol 6, 602
77 Swirski FK, Nahrendorf M, Etzrodt M et al (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616   DOI
78 Bleriot C, Dupuis T, Jouvion G et al (2015) Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection. Immunity 42, 145-158   DOI
79 Devisscher L, Scott CL, Lefere S et al (2017) Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cell Immunol 322, 74-83   DOI
80 Ramachandran P, Dobie R, Wilson-Kanamori JR et al (2019) Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512-518   DOI
81 Wang Y, Cella M, Mallinson K et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061-1071   DOI
82 Szabo G and Petrasek J (2015) Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 12, 387-400   DOI
83 Wehr A, Baeck C, Heymann F et al (2013) Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis. J Immunol 190, 5226-5236   DOI
84 Malehmir M, Pfister D, Gallage S et al (2019) Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 25, 641-655   DOI
85 Schneider KM, Bieghs V, Heymann F et al (2015) CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology 62, 1405-1416   DOI
86 Lambrecht J, van Grunsven LA and Tacke F (2020) Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 21, 1637-1650   DOI
87 Ju C and Tacke F (2016) Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel thera-peutic strategies. Cell Mol Immunol 13, 316-327   DOI
88 Krenkel O, Puengel T, Govaere O et al (2018) Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 67, 1270-1283   DOI
89 Mulder P, van den Hoek AM and Kleemann R (2017) The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and nonalcoholic steatohepatitis. PLoS One 12, e0169740   DOI
90 Albillos A, de Gottardi A and Rescigno M (2020) The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 72, 558-577   DOI
91 Bennett RG, Simpson RL and Hamel FG (2017) Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis. World J Gastroenterol 23, 3999-4006   DOI
92 Weiskirchen R and Tacke F (2016) Liver fibrosis: from pathogenesis to novel therapies. Dig Dis 34, 410-422   DOI
93 Tran S, Baba I, Poupel L et al (2020) Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. Immunity 53, 627-640.e5   DOI
94 Gao B and Tsukamoto H (2016) Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology 150, 1704-1709   DOI
95 Duffield JS, Forbes SJ, Constandinou CM et al (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115, 56-65   DOI
96 Lefere S, Degroote H, Van Vlierberghe H et al (2019) Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers. J Hepatol 71, 631-633   DOI
97 Jaitin DA, Adlung L, Thaiss CA et al (2019) Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686-698.e14   DOI
98 Hou J, Zhang J, Cui P et al (2021) TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest 131, e135197   DOI
99 Perugorria MJ, Esparza-Baquer A, Oakley F et al (2019) Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut 68, 533-546   DOI